ARCHIVES

Letters: Alternatives Needs Scrutiny, Investigator Open-Mindedness

This article is from The Cancer Letter archive.

Vol. 19 No. 47 | December 3, 1993

Download PDF Visit The Full Archive

Related Articles

DeVita: “The War On Cancer Is Dead”

June 11, 2010

DCE Board Approves Epidemiology Contract Recompetitions

March 17, 1995

Cancer Letter Editor Wine Reporting Awards

June 11, 1999

NCI To Offer Expanded Access To Oxaliplatin

May 31, 2002

Survival For ALL Increased To 94 Percent In Recent Years

December 31, 2010

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004